Handbook of Pharmaceutical Manufacturing Formulations, Third Edition (3rd Ed.) Volume Four, Semisolid Products
Auteur : Niazi Sarfaraz K.
The Handbook of Pharmaceutical Manufacturing Formulations, Third Edition: Volume Four, Semisolid Products is an authoritative and practical guide to the art and science of formulating drugs for commercial manufacturing. With thoroughly revised and expanded content, this fourth volume of a six-volume set, compiles data from FDA and EMA new drug applications, patents and patent applications, and other sources of generic and proprietary formulations including author?s own experience, to cover the broad spectrum of cGMP formulations and issues in using these formulations in a commercial setting. A must-have collection for pharmaceutical manufacturers, educational institutions, and regulatory authorities, this is an excellent platform for drug companies to benchmark their products and for generic companies to formulate drugs coming off patent.
Features:
Largest source of authoritative and practical formulations, cGMP compliance guidance and self-audit suggestions
Differs from other publications on formulation science in that it focuses on readily scalable commercial formulations that can be adopted for cGMP manufacturing
Tackles common difficulties in formulating drugs and presents details on stability testing, bioequivalence testing, and full compliance with drug product safety elements
Written by a well-recognized authority on drug and dosage form development including biological drugs and alternative medicines
Part I Regulatory and Manufacturing Guidance
Chapter 1. Waiver of In Vivo Bioequivalence Study
Chapter 2. Quality Risk Management
Chapter 3. Pharmaceutical Quality System
Chapter 4. Pharmaceutical Development
Chapter 5. Scale-Up and Postapproval Changes for Nonsterile Semisolid Dosage Forms: Manufacturing Equipment
Chapter 6. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
Chapter 7. Validation of Analytical Procedures
Chapter 8. Bioequivalence Testing of Topical Drugs
Chapter 9. Active Pharmaceutical Ingredients: GMP Compliance and Inspection
Chapter 10. Test Procedures and Acceptance Criteria for New Chemical Drug Substances and Drug Products
Chapter 11. Topical Testing of Transdermal Drug Products
Chapter 12. Impurities Profiling: Drug Substance
Chapter 13. Impurities in New Drug Products
Chapter 14. Formulation Factors in Semisolid Dosage Forms
Chapter 15. Pediatric Research Equity Act (PREA) Compliance
Chapter 16. Global Regulatory Guidance on Bioequivalence Testing
Chapter 17. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs – General Considerations
Chapter 18. FDA 483 Observations
Chapter 19. WHO Good Manufacturing Guidelines
Appendices
Part II Manufacturing Formulations
Semisolid Formulations
Part III Commercial Pharmaceutical Formulations
Commercial Pharmaceutical Formulations
Sarfaraz K. Niazi, Ph.D., a well-recognized authority on drug and dosage form development including biological drugs and alternative medicines. He is Founder and Executive Chairman of Adello Biologics, LLC, (formerly, Therapeutic Proteins International, LLC), a biosimilar products company located in Chicago, IL, Piscataway, NJ and Cashel, Ireland. As an entrepreneur, Niazi has raised hundreds of millions of dollars and became recognized as an inductee into the Chicago Entrepreneur Hall of Fame.Niazi began his career teaching pharmaceutical sciences at the University of Illinois, College of Pharmacy where he was tenured before entering the industry at Abbott International. He departed Abbott as an Abbott Volwiler Fellow to pursue his passion, first through global consulting and later through the founding a biosimilar products company.
A prolific inventor with scores of patents, most prominently in the field of bioprocessing technology, Niazi is currently the largest single holder of bioprocess technology patents. His other inventions span a broad category of technologies, new chemical entities, new formulations, new analytical methodologies, and much more. He has hands on experience in developing chemical, botanical and biological products, from discovery to regulatory approval. With over 50 ISBNs under his name, Niazi has authored many landmark books in the field of pharmaceutical sciences.
He currently serves as Adjunct Professor at the University of Illinois College of Pharmacy, Ad Hoc faculty at the University of Houston, Texas, the HEJ Research Institute, Karachi, and the National University of Science and Technology, Islamabad. He has also served as a Foreign Professor at the HEJ Research Institute, Karachi. He serves on the editorial board of the journal MOJ Proteomics & Bioinformatics (MOJPB) and starting 2017, as Chief Editor of International Journal of Biosimilars. He also serves as Member of National
Date de parution : 12-2019
21x28 cm
Thème de Handbook of Pharmaceutical Manufacturing Formulations... :
Mots-clés :
active pharmaceutical ingredients; bioequivalence testing; cGMP compliance; good manufacturing practice; Pre-approval inspections; in vivo bioequivalence study; Stability and bioequivalence testing; manufacturing guidance; Packaging commodity development; nonsterile semisolid dosage forms; Formulating drugs; pharmaceutical development; Changes to aNDAs; and aBLAs; pharmaceutical manufacturing formulations; bioequivalence; pharmaceutical quality system; c-goods manufacturing practice compliance; quality risk management; pharmaceutics; regulatory agencies; scalable commercial formulations; semisolid products; topical drugs; U.S; FDA; Edetate Disodium; Carbomer 934P; Dry Powder Inhalers; Topical Dermatological Drug Product; API Manufacturer; Drug Substance; Ich Q6A; Ich Q9; Ich Guideline; Drug Products; Dosage Forms; Vitro Release; Ich Guideline Q1A; API Process; Inactive Ingredients; Container Closure System; API; Quality Risk Management Process; Vitro Release Testing; Regional GMP Requirement; Stratum Corneum; Methyl Paraben
